188 related articles for article (PubMed ID: 37673172)
1. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
Agbana P; Park JE; Rychahou P; Kim KB; Bae Y
J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172
[TBL] [Abstract][Full Text] [Related]
2. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
[TBL] [Abstract][Full Text] [Related]
3. Effects of Organic Acids on Drug Release From Ternary Polypeptide Nanoparticles Entrapping Carfilzomib.
Jackson S; Agbana P; Kim KB; Bae Y
J Pharm Sci; 2022 Apr; 111(4):1172-1177. PubMed ID: 34551351
[TBL] [Abstract][Full Text] [Related]
4. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
[TBL] [Abstract][Full Text] [Related]
5. Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.
Reichel D; Lee MJ; Lee W; Kim KB; Bae Y
Ther Deliv; 2016 Oct; 7(10):665-681. PubMed ID: 27790952
[TBL] [Abstract][Full Text] [Related]
6. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
[TBL] [Abstract][Full Text] [Related]
7. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
9. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
Park JE; Park J; Jun Y; Oh Y; Ryoo G; Jeong YS; Gadalla HH; Min JS; Jo JH; Song MG; Kang KW; Bae SK; Yeo Y; Lee W
J Control Release; 2019 May; 302():148-159. PubMed ID: 30954620
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.
Jun Y; Xu J; Kim H; Park JE; Jeong YS; Min JS; Yoon N; Choi JY; Yoo J; Bae SK; Chung SJ; Yeo Y; Lee W
J Pharm Sci; 2020 Apr; 109(4):1615-1622. PubMed ID: 31945310
[TBL] [Abstract][Full Text] [Related]
11. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
[TBL] [Abstract][Full Text] [Related]
13. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
Zhang C; Wang X; Cheng R; Zhong Z
Biomacromolecules; 2020 Jun; 21(6):2049-2059. PubMed ID: 32338875
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib.
Thakur S; Ruan Y; Jayanthan A; Boklan J; Narendran A
Curr Cancer Drug Targets; 2021; 21(9):804-811. PubMed ID: 33949932
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
[TBL] [Abstract][Full Text] [Related]
16. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
[TBL] [Abstract][Full Text] [Related]
17. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myeloma.
Chen R; Yang J; Mao Y; Zhao X; Cheng R; Deng C; Zhong Z
Biomacromolecules; 2023 Nov; 24(11):5371-5380. PubMed ID: 37801632
[TBL] [Abstract][Full Text] [Related]
19. Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
Barbagallo I; Giallongo C; Volti GL; Distefano A; Camiolo G; Raffaele M; Salerno L; Pittalà V; Sorrenti V; Avola R; Di Rosa M; Vanella L; Di Raimondo F; Tibullo D
Mol Neurobiol; 2019 Feb; 56(2):1451-1460. PubMed ID: 29948946
[TBL] [Abstract][Full Text] [Related]
20. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]